Nizar Bahlis

1 month ago | nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more

AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).

Oct 20, 2024 | nature.com | Nizar Bahlis |Luciano Costa |Maria-Victoria Mateos |Ajay K. Nooka |Aurore Perrot |Alfred Garfall | +1 more

Dear Editor,The risk of infection in patients with multiple myeloma (MM) is high, particularly for those with relapsed/refractory MM (RRMM), who typically exhibit substantial immune dysfunction due to multiple prior therapies as well as MM itself [1, 2]. The recent COVID-19 pandemic had an impact on patients with MM compared with non-MM patients, including a higher risk of infection, a higher excess mortality rate, and decreased survival in 2020 compared with 2019 [3].

Jun 26, 2024 | nature.com | Nizar Bahlis

AbstractMultiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence. It remains incurable because most patients relapse or become refractory to treatments.

Feb 29, 2024 | onlinelibrary.wiley.com | Mohamad Mohty |Hôpital Saint-Antoine |Nizar Bahlis |Ajay K. Nooka

INTRODUCTION Multiple myeloma (MM) is associated with severe symptoms, including pain, fatigue and a decreased ability to perform and cope with activities of daily living; these symptoms have been strongly correlated with impairments in health-related quality of life (QOL) in these patients.1-4 Bone lesions, bone marrow and renal failure, and immunodeficiency contribute to many complications of the disease.4 Advances in anti-myeloma treatments have improved disease response rates and patient...